Haemophilia A Clinical Trials

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

NCT01493778

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Phoenix, Arizona, United States

Novo Nordisk Investigational Site Long Beach, California, United States

Novo Nordisk Investigational Site Sacramento, California, United States

Novo Nordisk Investigational Site Washington D.C., District of Columbia, United States

View all 69 locations

View Trial Details

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

NCT01731600

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Phoenix, Arizona, United States

Novo Nordisk Investigational Site Long Beach, California, United States

Novo Nordisk Investigational Site Orange, California, United States

Novo Nordisk Investigational Site Washington D.C., District of Columbia, United States

View all 51 locations

View Trial Details

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

NCT01480180

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Phoenix, Arizona, United States

Novo Nordisk Investigational Site Long Beach, California, United States

Novo Nordisk Investigational Site Sacramento, California, United States

Novo Nordisk Investigational Site Torrance, California, United States

View all 93 locations

View Trial Details

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.

NCT01489111

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Phoenix, Arizona, United States

Novo Nordisk Investigational Site Long Beach, California, United States

Novo Nordisk Investigational Site Sacramento, California, United States

Novo Nordisk Investigational Site Torrance, California, United States

View all 70 locations

View Trial Details

Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

NCT02938585

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Beijing, Beijing Municipality, China

Novo Nordisk Investigational Site Chonqqing, Chongqing Municipality, China

Novo Nordisk Investigational Site Fuzhou, Fujian, China

Novo Nordisk Investigational Site Guangzhou, Guangdong, China

View Trial Details

Completed

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

NCT02035384

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Mobile, Alabama, United States

Novo Nordisk Investigational Site Torrance, California, United States

Novo Nordisk Investigational Site Peoria, Illinois, United States

Novo Nordisk Investigational Site Albuquerque, New Mexico, United States

View all 41 locations

View Trial Details

Completed

Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period

NCT03449342

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Bangalore, Karnataka, India

Novo Nordisk Investigational Site Kochi, Kerala, India

Novo Nordisk Investigational Site Mumbai, Maharashtra, India

Novo Nordisk Investigational Site Pune, Maharashtra, India

View Trial Details

Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A

NCT02994407

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Orlando, Florida, United States

Novo Nordisk Investigational Site Iowa City, Iowa, United States

Novo Nordisk Investigational Site East Lansing, Michigan, United States

Novo Nordisk Investigational Site Cleveland, Ohio, United States

View all 19 locations

View Trial Details

Completed

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia

NCT03660774

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +10 more
Locations: Novo Nordisk Investigational Site Los Angeles, California, United States

Novo Nordisk Investigational Site Orange, California, United States

Novo Nordisk Investigational Site San Diego, California, United States

Novo Nordisk Investigational Site Aurora, Colorado, United States

View all 22 locations

View Trial Details

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B

NCT01228669

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +12 more
Locations: Novo Nordisk Investigational Site Vienna, Austria

Novo Nordisk Investigational Site Copenhagen, Denmark

Novo Nordisk Investigational Site Berlin, Germany

Novo Nordisk Investigational Site Frankfurt/M., Germany

View all 16 locations

View Trial Details

Haemophilia A

Haemophilia A trial results

Related conditions